Rafael Holdings, INC 8-K filings

Rafael Holdings, Inc. provided an investor presentation detailing the progress of its Trappsol Cyclo Phase 3 clinical trial for Niemann-Pick Disease Type C1, with NDA submission anticipated in the second half of 2026.

Rafael Holdings announced third quarter fiscal year 2026 financial results, highlighting the completion of the last patient last visit for its pivotal Phase 3 TransportNPC trial and an expected NDA submission in the second half of calendar 2026.

Rafael Holdings announced the completion of the last patient visit in its pivotal Phase 3 TransportNPC study for Trappsol Cyclo, with topline data expected in late 2026.

Rafael Holdings' subsidiary, Cyclo Therapeutics, has secured an exclusive license from MIT for a patent covering cyclodextrins in Alzheimer's patients with the ApoE4 genetic mutation.

Rafael Holdings announced its second quarter fiscal year 2026 financial results and positive progress in its pivotal Phase 3 TransportNPC study for Niemann-Pick Disease Type C1.

Rafael Holdings, Inc. announced the results of its Annual Meeting, including the election of directors, ratification of its auditor, and approval of an amended equity incentive plan.

Rafael Holdings, Inc. announced its first quarter fiscal year 2026 financial results, reporting an increased net loss primarily due to the consolidation of Cyclo Therapeutics expenses, while its pivotal Phase 3 TransportNPC study continues to progress.

Rafael Holdings, Inc. announced the issuance of 1,078,796 warrants for Class B common stock following its merger with Cyclo Therapeutics, Inc.

Rafael Holdings announced its fourth quarter and full fiscal year 2025 financial results, highlighting progress in its pivotal Phase 3 TransportNPC study and an enhanced financial position.

Rafael Holdings announced the appointment of Alan Grayson to its Board of Directors and Markus Sieger as Audit Committee Chair, following the passing of Lead Independent Director Stephen Greenberg.

Rafael Holdings announced its Phase 3 clinical trial for Trappsol Cyclo in Niemann-Pick Disease Type C1 will continue to final analysis after a positive interim review.

Rafael Holdings, Inc. details significant executive transitions, including a new COO, and severance and consulting agreements for departing officers.

Rafael Holdings, Inc. announced the election of N. Scott Fine as an ex-officio (non-voting) director and Vice Chairman, alongside the adoption of Fourth Amended and Restated By-Laws to formalize new director roles and officer positions.

Rafael Holdings, Inc. announced that its pivotal Phase 3 TransportNPC study for Niemann-Pick Disease Type C1 (NPC1) will continue to its full 96-week duration following a positive independent Data Monitoring Committee review of interim safety and efficacy data.

Rafael Holdings, Inc. announced a significant reduction in net losses for its third fiscal quarter and first nine months of 2025, driven by the absence of prior year's large non-cash expenses, while confirming the completion of its merger with Cyclo Therapeutics and a $25 million rights offering, with pivotal Phase 3 clinical trial results for Trappsol Cyclo expected later this month.

Rafael Holdings, Inc. announced the completion of its $25.0 million rights offering, which was significantly under-subscribed by public shareholders and subsequently backstopped by CEO Howard S. Jonas and related parties, securing approximately $24.9 million in net proceeds.

Rafael Holdings provides an update on the subscription rights related to its Public Warrants in connection with its previously announced $25 million rights offering.

Rafael Holdings, Inc. has entered into a Standby Purchase Agreement with its Executive Chairman, Howard S. Jonas, to backstop a $25 million rights offering of Class B Common Stock.

Rafael Holdings announces revised subscription rights for its previously announced $25 million rights offering to support the development of Trappsol Cyclo.

Rafael Holdings plans a $25 million rights offering to support the potential launch of Trappsol Cyclo, a treatment for Niemann-Pick Disease Type C1.

Rafael Holdings finalizes its acquisition of Cyclo Therapeutics, aiming to advance cyclodextrin-based treatments for neurodegenerative diseases.

Rafael Holdings announces that Bill Conkling will step down as CEO, with Howard Jonas stepping in, following the merger with Cyclo Therapeutics.

Rafael Holdings completes its merger with Cyclo Therapeutics, issuing shares and warrants, and anticipates interim results from the TransportNPC Phase 3 trial in mid-2025.

Rafael Holdings' stockholders have approved the issuance of shares for the proposed merger with Cyclo Therapeutics at a special meeting held on March 20, 2025.

Rafael Holdings reported its Q2 fiscal year 2025 financial results and anticipates closing its merger with Cyclo Therapeutics in Q3, with a strategic focus on Trappsol Cyclo post-merger.

Rafael Holdings and Cyclo Therapeutics have amended their merger agreement, extending the deadline for completion to March 31, 2025.

Rafael Holdings, Inc. held its annual meeting on January 9, 2025, where stockholders voted on the election of directors, ratification of the accounting firm, and an amendment to the equity incentive plan.

Rafael Holdings converted $2.5 million of its convertible note in Cyclo Therapeutics into 3,968,254 shares, increasing its ownership to 39.5%.

Rafael Holdings reported a net loss of $9.0 million for the first quarter of fiscal year 2025, driven by unrealized losses on its investment in Cyclo Therapeutics, as it prepares for a merger with the company.

Rafael Holdings announced its fourth quarter and full fiscal year 2024 results, highlighting a proposed merger with Cyclo Therapeutics and progress in its clinical stage asset development strategy.